Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid.

Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid. Abstract Text:

J G Lussier,T D Carruthers,

This study examined the effects of altered serum FSH concentration on subsequent ovarian response to superovulation. Synchronized heifers were assigned randomly on Day 1 of the cycle (estrus = Day 0) to three pretreatment groups that consisted of 6-d of saline (7ml, s.c., b.i.d.; Group I), FSH-P (0.5 mg, i.m., b.i.d.; Group II) or charcoal-extracted bovine follicular fluid (BFF; 7 ml, s.c., b.i.d.; Group III) injections. Superovulation was initiated on Day 7 and consisted of FSH-P in decreasing dosages over 4 d (4,3,2,1 mg; i.m., b.i.d.), with cloprostenol (500 mug) on the morning of the third day. A second replicate with 14 heifers was conducted using the same protocol but twice the pretreatment dosage of FSH-P (1 mg) and BFF (14 ml). Endogenous plasma FSH decreased during BFF and FSH-P pretreatments compared to controls (P < 0.02). Endogenous FSH concentrations in both primed groups (II and III) were similar to control values (Group I) 12 h after the start of superovulation. Basal LH concentrations were not different between pretreatment groups. The interval from cloprostenol treatment to the preovulatory LH surge in Group III was 21.3 and 23.9 h longer (P < 0.0001) than it was in Groups I and II. The postovulation progesterone rise was delayed in Group III. The number of corpora lutea (CL) was lowest in the BFF-primed group (4.2 +/- 0.8) compared with the FSH-primed (7.4 +/- 1.3) and the control (12.0 +/- 1.8; P < 0.003) groups. In the FSH-primed group (0.68 +/- 0.06 cm(3)), CL volumes were larger than in the control group (0.45 +/- 0.03 cm(3)), whereas in the BFF-primed group (0.27 +/- 0.02 cm(3)) CL volumes were smaller compared with the control group (P < 0.0001). Mean FSH concentrations for 48 h preceding superovulation and the number of CL per cow were positively correlated (r = 0.55; P < 0.004; n = 26). We concluded that both FSH-P and BFF pretreatments decreased the superovulatory response of heifers to FSH-P. The mechanism for this would appear to be associated with reduced endogenous FSH prior to the start of superovulation.

Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid. Publishing Authors By Initials

JG Lussier,TD Carruthers,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Theriogenology

VOLUME: 31

Page Numbers: 779-94

Journal Abbreviation: Theriogenology

ISSN: 0093-691X

DAY: 26

MONTH: Apr

YEAR: 1989

Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 421510

Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid.

AFFILIATION: Agriculture Canada Research Station, C.P.90 Lennoxville, Québec, Canada, J1M 1Z3.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Theriogenology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid Related Publications

• 2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.
• A cleavable propeptide influences Toxoplasma infection by facilitating the trafficking and secretion of the TgMIC2-M2AP invasion complex.
• A transient forward-targeting element for microneme-regulated secretion in Toxoplasma gondii.
• ATP-dependent sugar transport complexity in human erythrocytes.
• Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.
• Broadening discussions of "safe" in hepatitis C prevention: A close-up of swabbing in an analysis of video recordings of injecting practice.
• Caveat emptor (buyer beware).
• Discussion: the history of injectable silicone fluids for soft-tissue augmentation.
• Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores.
• Elderly patients with hypertension should retain 'special' status.
• Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid.
• Host cell manipulation by the human pathogen Toxoplasma gondii.
• Hyaluronidase in the office: a necessity for every dermasurgeon that injects hyaluronic acid.
• Laboratory testing of spermicidal preparation.
• Lead identification of acetylcholinesterase inhibitors-histamine H(3) receptor antagonists from molecular modeling.
• MARveling at parasite invasion.
• Mad cows, prions, and wrinkles.
• Malakoplakia: report of a case.
• Patient-reported outcomes with botulinum neurotoxin type A.
• Recent medicinal chemistry of the histamine H3 receptor.
• Reminders in echocardiography reports increased use of blockers in reduced left ventricular ejection fraction.
• Shrinking upper and lower eyelid skin with a novel radiofrequency tip.
• Some points in the diagnosis of labyrinthine vertigo and a survey of methods of treatment, medical and surgical.
• Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.
• The J-curve--it is clinically relevant?
• The diagnosis of late life hypogonadism.
• The evolution of botulinum neurotoxin type A for cosmetic applications.
• The organization of a community: community-based prevention of injecting drug use-related health problems.
• The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action.
• [Not Available.]